Gastric acid measurement is useful in assessing the effectiveness of antisecretory drugs, however, the conventional tests involve invasive nasogastric intubation. Orally administered 13 C-labeled calcium carbonate (Ca 13 CO 3 ) reacts with gastric acid to produce 13 C-labeled carbon dioxide ( 13 CO 2 ), which is then excreted in the breath. The objective of this study was to evaluate the suitability of Ca 13 CO 3 breath test for estimating gastric acid secretion in human noninvasively. First, the Ca 13 CO 3 breath test and the measurement of pooled gastric acid under a fasting condition were performed in 6 healthy volunteers to evaluate the correlation between the two parameters. Next, endoscopic gastric acid collection and the Ca 13 CO 3 breath test were performed on different days after pentagastrin injection in 20 subjects to evaluate the correlation between the tests and the reproducibility. Finally, the same studies were repeated in 4 subjects before and after 1-week rabeprazole, a proton pump inhibitor, administration. The maximum 13 CO 2 concentration (Cmax) correlated very well with the amount of pooled gastric acid (r = 0.95), suggesting that Ca 13 CO 3 breath test values well reflected the fasting intragastric acidity. The 13 CO 2 concentration after pentagastrin injection correlated well with pentagastrin-stimulated maximal acid output (r = 0.79 at 20 min). The reproducibility of the Ca 13 CO 3 breath test under pentagastrin-stimulation was good (coefficient of variation = 0.11). Rabeprazole administration markedly reduced the values of the Ca 13 CO 3 breath test, suggesting that it can sensitively assess the efficacy of rabeprazole. The Ca 13 CO 3 breath test can potentially be a useful method for non-invasive estimation for gastric acid secretion in human.
Introduction
Gastro-esophageal reflux disease (GERD) is a common disease in Western countries (Locke et al. 1997; Stanghellini et al. 1999; Diaz-Rubio et al. 2004) , and the number of patients with GERD is increasing in Japan as well (Inamori et al. 2003; Fujimoto et al. 2003; Fujiwara et al. 2005) . Gastric acid has an important role as the dominant injurious factor in the pathogenesis of GERD. The primary therapeutic approach is suppression of gastric acid secretion, and stronger and prompter gastric acid suppression is required (Bell et al. 1992) . Proton pump inhibitors (PPIs) are commonly used as the first-line treatment because of the high effectiveness and prolonged duration of suppression of gastric acid secretion. Thus, the therapeutic effects of PPIs on GERD are associated with the gastric acidity.
Gastric acidity is different in various disease states and their measurement may be useful in the diagnosis and treatment of these diseases. High levels of acidity are found in duodenal ulcers and patients with Zollinger-Ellison syndrome, whereas low or absent levels of acidity are found in pernicious anemia, atrophic gastritis and gastric carcinoma (McColl et al. 1997) . Gastric acid measurement may also be useful in assessing the effectiveness of new antisecretory drugs.
The conventional tests of measuring gastric acid secretion involve nasogastric intubation into the stomach and continuous aspiration of gastric fluid for a few hours (Kay 1953; Johnston and Jepson 1967) . The procedure of these invasive tests causes significant distress to the patients and is time consuming. To estimate gastric acid secretion easily and rapidly, we previously devised an endoscopic method of gastric acid secretory testing (endoscopic gastrin test: EGT), which is a simple modification of the conventional gastrin-stimulated maximal acid output test (Iijima et al. 1998) . However, the endoscopic procedure still causes some discomfort in the subjects, hence repeating EGT is not always easy. Therefore, the development of a non-invasive method would be desirable. 13 C is a non-radioactive stable isotope of carbon and is widely used in clinical settings, such as in the 13 C-urea breath test for the diagnosis of Helicobacter pylori infection (Graham et al. 1987) . 13 CO 2 is absorbed rapidly by the gastric wall and delivered through the bloodstream to the lungs, and finally excreted in the breath. Thus, the amount of exhaled 13 CO 2 is expected to correlate with the amount of pooled gastric acid. Then, by measuring the ratio of 13 CO 2 to 12 CO 2 in the breath sample via an infrared spectrophotometer, the amount of gastric acid can be estimated.
The objective of this study was to evaluate the suitability of the Ca 13 CO 3 breath test for measuring gastric acid secretion in human. First, we evaluated correlations between the breath response and gastric secretory parameters under fasting and pentagastrin stimulated conditions. In addition, we also evaluated the reproducibility of the breath test results under the same conditions. Then, we evaluated weather the Ca 13 CO 3 breath test results reflected the change in gastric acid secretion induced by PPIs administration.
Methods

Study protocols
First, to evaluate the correlation between the results of the Ca 13 CO 3 breath test and the total amount of pooled gastric acid under a fasting condition, 6 healthy volunteers (mean age 23.0 ± 1.3 years) underwent endoscopic examination after overnight fast, and the pooled gastric acid was collected. Two hours after endoscopy, the Ca 13 CO 3 breath test was performed under a fasting condition. Then, the series of studies were repeated six times on different days with different doses of Ca 13 CO 3 to determine the appropriate dose of Ca 13 CO 3 .
Next, to evaluate the correlation between Ca
13
CO 3 breath test values and the amount of modified gastric acid output (EGT value) under pentagastrin-stimulation, 20 participants (mean age 39.8 ± 18.0 years) were enrolled. Of them, 15 were healthy volunteers, and the other 5 were diagnosed with atrophic gastritis. The subjects with atrophic gastritis did not receive acid suppressive drugs. They underwent EGT as mentioned below, in which gastric fluid was collected endoscopically after pentagastrin injection. On a different day, the Ca 13 CO 3 breath test was performed 20 min after intramuscular injection of pentagastrin. The reproducibility of the Ca 13 CO 3 breath test was estimated by repeating the same test on different days.
Finally, to evaluate whether the Ca 13 CO 3 breath test results reflected the change in gastric acid secretion by PPIs, 4 healthy volunteers were given oral rabeprazole at a dose of 10 mg twice daily for a week. Then, endoscopic gastric acid collection (EGT) and Ca 13 CO 3 breath test under pentagastrin stimulation were repeated before and after rabeprazole administration.
The study was performed in accordance with the Declaration of Helsinki. The study protocol was approved by the ethics committee of the Tohoku University Graduate School . Subjects provided written informed consent before participating.
Measurement of the amount of pooled gastric fluid
After an overnight fast, pooled gastric fluid was obtained by aspiration through an endoscope. The H + concentration was determined by titration. The total amount of pooled gastric acid was calculated by multiplying the volume with the concentration, and was expressed as H + mEq. CO 3 suspended in 50 ml of carboxymethylcellulose sodium (CMC-Na) on each occasion. The participants were in an upright sitting position during the breath test. Breath samples were collected in breath collection bags before and 5, 10, 15, 20, 25, 30, 40, 50, 60, 80, 100 , and 120 min after dosing. The 13 CO 2 concentration in each breath sample was measured using an infrared spectral analyzer (POCone; Otsuka Electronics Co., Ltd., Hirakata, Japan).
Endoscopic Gastrin Test (EGT)
The details of the EGT have been reported previously (Iijima et al. 1998) . Briefly, after an overnight fast, subjects were injected intramuscularly with pentagastrin at a dose of 6 μg/kg (pentagastrin; Sigma, St. Louis, MO, USA). 15 min after the injection, an endoscope was inserted into the stomach, and pooled gastric fluid was aspirated and discarded. Gastric fluid secreted between 20 and 30 min after the pentagastrin injection was then aspirated and collected under direct visualization during routine endoscopic examination of the stomach and duodenal bulb. The volume of the sample collected over the 10-min period was recorded, and the H + concentration was determined by titration. The acid output in the 10-min period was calculated by multiplying the volume by the H + concentration, and the EGT value was expressed as H + mEq/10 min.
Calcium carbonate (Ca 13 CO 3 ) breath test under pentagastrin-stimulated gastric acid secretion
After an overnight fast, subjects were injected intramuscularly with pentagastrin at a dose of 6 μg/kg. A single oral dose of 500 mg of Ca 13 CO 3 suspended in 0.5% CMC-Na was administered 20 min after the injection. A baseline breath sample was collected before injection. Breath samples were collected 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 60, 80, 100 , and 120 min after dosing. The participants were in an upright sitting position during the breath test. The 13 CO 2 concentration in each breath sample was measured using an infrared spectral analyzer. 13 Where Δ
Analysis of
13
C t is the change in the δ 13 C value measured at the time t (Δ 13 C t ) from the baseline (Δ 13 C 0 ) following the administration of 13 C-product.
Statistical analyses
The data are expressed as mean values ± standard deviation (s.d.). The breath test results were defined as the maximum 13 CO 2 concentration during the 120 min sampling period (Cmax) or a value at a specific time point. A liner regression analysis was carried out to evaluate proportionality between the dose levels of Ca 13 CO 3 and the breath-Cmax. Correlations between the Ca 13 CO 3 breath test values and the EGT values were assessed using linear regression analysis. The reproducibility of the tests was assessed by the coefficient of variation (CV).
Results
The mean 13 (Fig. 1B) , and reached a plateau when 500 and 1,000 mg of Ca 13 CO 3 were administered (Fig. 1C) . The Cmax correlated very well with Ca 13 CO 3 doses up to 200 mg (r = 0.87). Hence, 200 mg was considered an appropriate dose of Ca 13 CO 3 in this experimental condition. There was a very good correlation between the Cmax and the total amount of pooled gastric acid, when 200 mg of Ca 13 CO 3 were administered (r = 0.947). This correlation became even slightly higher when the 13 CO 2 values were modified by height and body weight, as shown in the appendix (r = 0.951, Fig. 1D ). Therefore, the following results are presented using 13 CO 2 values modified by height and body weight, and are expressed as %dose/hr. It was clearly demonstrated that the Ca 13 CO 3 breath test values well reflected the fasting intragastric acidity.
However, the reproducibility of the total amount of pooled gastric acid under a fasting state turned out to be poor in that the CV was 0.74 (data not shown). Because of the poor reproducibility, we could not expect satisfactory reproducibility for the Ca 13 CO 3 breath test under a fasting state, as well. Hence, we employed pentagastrin as a gastric stimulant to make the Ca 13 CO 3 breath test reproducible since high reproducibility of the maximal acid output after pentagastrin injection was reported (Card and Marks 1960) . Then, we performed the Ca 13 CO 3 breath test under pentagastirin-stimulated gastric acid secretion. In our previous study (Iijima et al. 1998) , the mean EGT value representing the amount of gastric acid secreted between 20 and 30 min after the pentagastrin injection was 3.6 mEq. On the other hand, the mean amount of pooled gastric acid in this study was 1.4 mEq. Hence, we considered that an approximately 2.5 fold higher dose of Ca 13 CO 3 is required under pentagastirin stimulation. Therefore, we used 500 mg of Ca 13 CO 3 , which was expected to maintain a linear correlation between the Ca 13 CO 3 dose and the Δ 13 CO 2 of the breath test under pentagastrin stimulation.
The mean Δ
13
CO 2 versus the time curves after oral administration of 500 mg of Ca 13 CO 3 after pentagastrin injection is shown in Fig. 2 CO 2 under pentagastrinstimulation was consistently higher than that without pentagastrin-stimulation at any measuring time point, and the Cmax under pentagastrin-stimulation was 2.7 times higher than that without pentagastrin-stimulation (data was not shown). The Cmax thus acquired in the stimulated Ca 13 CO 3 breath tests well correlated with the EGT value (Fig. 3A , r = 0.72). The high correlation between the stimulated Ca 13 CO 3 breath test and the EGT value was evident even when a one point sampling value of the breath test was applied in place of the Cmax. In particular, the Δ 13 CO 2 at 20 min after dosing showed the highest correlation with the EGT value (r = 0.79), suggesting that the Ca 13 CO 3 breath test can be performed as a simple and reliable procedure with one-point sampling for the measurement of gastric acid secretion in human (Fig. 3B) . In addition, the stimulated Ca 13 CO 3 breath tests were repeated in 4 participants to evaluate the reproducibility. Consequently, the reproducibility of the breath test was good with a CV of 0.11, as shown in Fig. 4 . CO 2 after rabeprazole administration dramatically decreased and nearly flattened at each measuring time point, and the Cmax decreased from 61.6 ± 7.5 %dose/hr to 8.1 ± 5.8 %dose/hr. Meanwhile, rabeprazole administration reduced the mean EGT value from 3.7 ± 1.5 mEq/10 min to 0.17 ± 0.25 mEq/10 min in the same participants.
Discussion
This study shows the usefulness of the Ca There was a very good correlation between the Cmax and the total amount of fasting pooled gastric acid (r = 0.95), suggesting that the Ca 13 CO 3 breath test results well reflected the fasting intragastric acidity at any given time. The chemical property of Ca 13 CO 3 , which is poorly watersoluble, but reacts immediately with hydrochloric acid in the stomach producing 13 CO 2 , which is excreted in the breath at a high rate, would be responsible for the high correlation between the breath test and the amount of pooled intragastric acid. These results are consistent with those of a study in rats reported by Inada et al. (2012) , in which the Ca 13 CO 3 breath test with or without proton pump inhibitors or pentagastrin showed a high correlation between the breath-Cmax and the total amount of gastric acid (r = 0.994). Thus, the Ca 13 CO 3 breath test can be a potentially promising candidate as a noninvasive test for measuring gastric acid secretion in human.
High reproducibility is essential to establishing a new biological test, and is especially true for gastric secretory testing because it is well-known that the gastric secretory state shows wide-variation in daily life. Nonetheless, the reproducibility of the total amount of pooled gastric acid without any stimulants was poor in the present study (CV = 0.74), consistent with a previous study showing poor reproducibility of a gastric fluid analysis in the basal state (White and Juniper 1973) . Therefore, the Ca 13 CO 3 breath test value under fasting could fluctuate in repeating tests, albeit each test value could reflect the fasting intragastric acidity at a given time. Actually, in 4 subjects who repeated the Ca 13 CO 3 breath test three times without gastric stimulants, the test results considerably varied with the CV of 0.25 (data not shown). To enhance the reproducibility, usage of a gastric acid stimulant such as test meals or drugs have been reported (Kay 1953; Ward et al. 1963; Lawrie and Forrest 1965) . In particular, pentagastrin has frequently been used as a gastric acid stimulant in gastric secretory testing. Gastric acid measurements using pentagastrin have been found to be reproducible in several studies including our case of EGT (Johnston and Jepson 1967; Iijima et al. 1998) . Therefore, in the present Ca 13 CO 3 breath test, we applied pentagastirin injection as a gastric acid stimulant to enhance its reproducibility.
With the aid of pentagastrin stimulation, the reproducibility of the Ca 13 CO 3 breath test became much improved, with a CV as low as 0.11, compared to that without any stimulants (CV = 0.25). At the same time, the stimulated Ca 13 CO 3 breath test (Cmax or the Δ 13 CO 2 at 20 min) retained a good correlation with the EGT values, which is a simplified index of the conventional maximal acid output. In addition, using this stimulated Ca 13 CO 3 breath test, a representative one-point sampling value in place of the Cmax obtained from multiple samplings for 2 hours turned out to be well correlated with the EGT values. Especially, the Δ 13 CO 2 at 20 min after Ca 13 CO 3 administration showed the best correlation with the EGT value (r = 0.79), suggesting that the Ca 13 CO 3 breath test can be performed as a simple and reliable procedure with one-point sampling for the estimation of gastric acid secretion in human.
Further, we explored the effects of PPI administration on the results of the stimulated Ca 13 CO 3 breath test to determine its clinical suitability and found that 1-week PPI administration caused a prominent reduction in the breath response (Δ 13 CO 2 ), along with a profound reduction of the actual gastric acid secretion estimated by the EGT, suggesting that the Ca 13 CO 3 breath test could be useful for evaluating the antisecretory effect of PPI. In GERD patients, at present, 24-hour intragastric pH monitoring is occasionally employed to determine whether the PPIs effectively inhibit gastric acid secretion. In that procedure, a pH-measuring electrode has to be inserted in the stomach through the nasogastric route, which is uncomfortable and restricts the physical activity of the patient. In contrast, the Ca 13 CO 3 breath test can provide information regarding the efficacy of PPI in a noninvasive and simple manner.
Some attempts to apply breath tests for measuring gastric acid secretion have been previously reported, but the tests have not been employed in clinical practice. Sack and Stephenson (Sack and Stephensen 1985; Stephensen et al. 1987 ) performed a hydrogen breath test for estimating gastric acid by oral magnesium administration in 1985. In their test, administered magnesium reacts with gastric acid to produce hydrogen gas, the amount of which reflects the gastric acid. The hydrogen concentration was measured by gas chromatography of the breath samples. A relatively good correlation coefficient of 0.70 was found between the conventional stimulated acid output values and the excess amount of hydrogen exhaled during the test. However, it could be difficult for this test to detect gastric acid secretion because substantial amounts of hydrogen gas exist in the exhaled air in some pathological conditions, especially in patients with intestinal bacterial overgrowth (Armbrecht et al. 1985) . In addition, magnesium in its metallic form has not yet been approved for clinical use in many countries including Japan, whereas the clinical use of ordinary Ca 12 CO 3 has been widespread as an antacid. Furthermore, exhaled hydrogen monitoring by gas chromatography is less popular than exhaled 13 CO 2 measurement by spectral analyzer.
Clough and Axon (2009), using the same compositional Ca 13 CO 3 as in our study, first reported the potential usefulness of a calcium carbonate breath test as a noninvasive method of quantifying the maximal acid secretion. In their test, excessive amounts of Ca 13 CO 3 (e.g. 500 mg every 5 min or 750 mg every 10 min up to several hours) were administered to induce maximal gastric acid secretion by the feedback stimulation resulting from the neutralization of gastric acid by the antacid action of Ca 13 CO 3 . The procedure seemed to successfully induce near maximal gastric acid secretion without using a pharmacological gastric stimulant such as pentagastrin. However, the test was performed in a single subject and was not compared with a conventional test, and the procedure was somewhat bothersome and time consuming. Moreover, the extensive use of costly Ca 13 CO 3 lacks versatility for daily clinical practice. Compared to this test, the present Ca 13 CO 3 breath test could simply and reliably assess the gastric acid output in a shorter time, although our test requires pentagastrin injection.
There may be a limitation of this study. Although the overall correlation between the stimulated Ca 13 CO 3 breath test and EGT value was good, the regression line did not pass the origin of the coordinates and was relatively gentle (Fig. 3A and B) . This suggests that the breath test is not a quantitative test of acid secretion over the range studied although it is useful as a qualitative test to pick up severe hypochlorhydria. Further studies are required to investigate appropriate test conditions to improve the ability of quantitative measurement of wide range of gastric acid secretion level. In addition, gastric motility such as gastric emptying may affect the breath test results by loss of acid secretion through the pylorus prior to the Ca 13 CO 3 administration. However, once Ca 13 CO 3 is administered into the stomach, gastric emptying should rarely affect the rate of the reaction occurring in the stomach since chemical reaction between Ca 13 CO 3 and hydrochloric acid proceeds promptly. In conclusion, the Ca 13 CO 3 breath test could be a simple, noninvasive method for estimating gastric acid secretion in human, and the test may be suitable for the clinical management of acid-related diseases. The development of ideal test meals as an alternative to pentagastrin injection
